| Drug Name |
Anidulafungin |
| Drug ID |
BADD_D00143 |
| Description |
Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. |
| Indications and Usage |
For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis. |
| Marketing Status |
approved; investigational |
| ATC Code |
J02AX06 |
| DrugBank ID |
DB00362
|
| KEGG ID |
D03211
|
| MeSH ID |
D000077612
|
| PubChem ID |
166548
|
| TTD Drug ID |
D0F9BY
|
| NDC Product Code |
0009-0043; 11722-054; 0049-0114; 62227-007; 65727-072; 68254-0013; 0049-0116 |
| UNII |
9HLM53094I
|
| Synonyms |
Anidulafungin | 1-((4R,5R)-4,5-Dihydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-L-ornithine)-echinocandin B | LY 303366 | LY303366 | LY-303366 | Eraxis |
